Early toxicity predicts long-term survival in high-grade glioma

British Journal of Cancer

Volumn 104, Issue 9, 2011, Pages 1365-1371

  Lawrence, Y R ^a,b   Wang, M ^c   Dicker, A P ^a   Andrews, D ^d   Curran, W J ^e   Michalski, J M ^f   Souhami, L ^g   Yung, W K ^h   Mehta, M ⁱ  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

^c RADIATION THERAPY ONCOLOGY GROUP   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MCGILL UNIVERSITY   (Canada)

^h UNIVERSITY OF TEXAS   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

Author keywords

glioblastoma; normal tissue effects; radiation therapy; toxicity

Indexed keywords

BETA INTERFERON; BLEOMYCIN; CARMUSTINE; DIAZIQUONE; PACLITAXEL; TAMOXIFEN; TEMOZOLOMIDE; THALIDOMIDE; TIRAPAZAMINE; TOPOTECAN;

ACUTE TOXICITY; ADULT; ARTICLE; ASSOCIATION; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHRONIC TOXICITY; FUNCTIONAL STATUS; GLIOBLASTOMA; GROUPS BY AGE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MENTAL HEALTH; NEUROLOGIC DISEASE; NEUROTOXICITY; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; RADIATION DOSE; RISK FACTOR; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; DOSE FRACTIONATION; FEMALE; GLIOMA; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK FACTORS; SUPRATENTORIAL NEOPLASMS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 79955472559     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.123     Document Type: Article

References (37)

1. Artz AS, Pollyea DA, Kocherginsky M, Stock W, Rich E, Odenike O, Zimmerman T, Smith S, Godley L, Thirman M, Daugherty C, Extermann M, Larson R, van Besien K (2006) Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 12: 954-964
2. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9: 453-461 (Pubitemid 351597795)
3. Brian NS, Nicholas JP, Harold OD, Deborah LD, Giuseppina A, Neal JM (1995) Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 75: 11-17
4. Cardinale R, Won M, Choucair A, Gillin M, Chakravarti A, Schultz C, Souhami L, Chen A, Pham H, Mehta M (2006) A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. Int J Radiat Oncol Biol Phys 65: 1422-1428 (Pubitemid 44425201)
5. Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE (2007) Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82: 81-83
6. Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S, Weinstein A, Nelson JS, Tsukada Y (1983) Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 52: 997-1007
7. Colman H, Berkey BA, Maor MH, Groves MD, Schultz CJ, Vermeulen S, Nelson DF, Mehta MP, Yung WK (2006) Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblas-toma: results of RTOG 9710. Int J Radiat Oncol Biol Phys 66: 818-824 (Pubitemid 44436691)
8. Coughlin C, Scott C, Langer C, Coia L, Curran W, Rubin P (2000) Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (420 or r20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients. Int J Radiat Oncol Biol Phys 48: 1351-1358
9. Cross NE, Glantz MJ (2003) Neurologic complications of radiation therapy. Neurol Clin 21: 249-277 (Pubitemid 36169351)
10. Curran Jr WJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE, Nelson DF (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85: 704-710 (Pubitemid 23133591)
11. Curran Jr WJ, Scott CB, Nelson JS, Weinstein AS, Phillips TL, Murray K, Fischbach AJ, Yakar D, Schwade JG, Powlis WD, Nelson DF (1992) A randomized trial of accelerated hyperfractionated radiation therapy and bis-chloroethyl nitrosourea for malignant glioma. A preliminary report of Radiation Therapy Oncology Group 83-02. Cancer 70: 2909-2917
12. Del Rowe J, Scott C, Werner-Wasik M, Bahary JP, Curran WJ, Urtasun RC, Fisher B (2000) Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. J Clin Oncol 18: 1254-1259 (Pubitemid 30159843)
13. 0Fallon JR, Buckner JC, Scheithauer BW, Krook JE, Tschetter LK, Maier JA (1993) Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma. J Clin Oncol 11: 1316-1321 (Pubitemid 23199136)
14. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71: 2585-2597 (Pubitemid 23100496)
15. Fisher B, Won M, Macdonald D, Johnson DW, Roa W (2002) Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group 9513. Int J Radiat Oncol Biol Phys 53: 980-986 (Pubitemid 34722645)
16. Fowler JF (1989) The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 62: 679-694 (Pubitemid 19194494)
17. Gerstner E, McNamara M, Norden A, LaFrankie D, Wen P (2009) Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neurooncol 94: 97-101
18. Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, Guillamo J-S, Jadaud E, Colin P, Bondiau P-Y, Menei P, Loiseau H, Bernier V, Honnorat J, Barrie M, Mokhtari K, Mazeron J-J, Bissery A, Delattre J-Y, The Association of French-Speaking N-O (2007) Radiotherapy for glioblastoma in the elderly. N Engl J Med 356: 1527-1535
19. Kumar Pal S, Katheria V, Hurria A (2010) Evaluating the older patient with cancer: understanding frailty and the geriatric assessment. CA Cancer J Clin 60: 120-132
20. Langer CJ, Ruffer J, Rhodes H, Paulus R, Murray K, Movsas B, Curran W (2001) Phase II radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme. Int J Radiat Oncol Biol Phys 51: 113-119 (Pubitemid 32758870)
21. Lawrence YR, Li XA, el Naqa I, Hahn CA, Marks LB, Merchant TE, Dicker AP (2010) Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys 76: S20-S27
22. Lee AW, Foo W, Chappell R, Fowler JF, Sze WM, Poon YF, Law SC, Ng SH, O SK, Tung SY, Lau WH, Ho JH (1998) Effect of time, dose, and fractionation on temporal lobe necrosis following radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 40: 35-42 (Pubitemid 28027564)
23. Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R (2006) Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24: 2563-2569 (Pubitemid 46630635)
24. Mizumatsu S, Monje ML, Morhardt DR, Rola R, Palmer TD, Fike JR (2003) Extreme sensitivity of adult neurogenesis to low doses of X-irradiation. Cancer Res 63: 4021-4027 (Pubitemid 36917922)
25. Robins HI, Won M, Seiferheld WF, Schultz CJ, Choucair AK, Brachman DG, Demas WF, Mehta MP (2006) Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021. Neuro Oncol 8: 47-52 (Pubitemid 43154450)
26. Scott C, Curran JW, Yung W, Scarantino C, Urtasun R, Movsas B, Jones C, Simpson J, Fischbach A, Petito C, Nelson J (1998a) Long term results of RTOG 9006: a randomized trial of hyperfractionated radiotherapy (RT) to 72.0 Gy & carmustine vs standard RT & carmustine for malignant glioma patients with emphasis on anaplastic astrocytoma (AA) patients. (Abstract 1546) Proc Am Soc Clin Oncol
27. Scott CB, Scarantino C, Urtasun R, Movsas B, Jones CU, Simpson JR, Fischbach AJ, Curran Jr WJ (1998b) Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys 40: 51-55 (Pubitemid 28027566)
28. Shinoda J, Sakai N, Murase S, Yano H, Matsuhisa T, Funakoshi T (2001) Selection of eligible patients with supratentorial glioblastoma multiforme for gross total resection. J Neurooncol 52: 161-171 (Pubitemid 32691179)
29. Souhami L, Seiferheld W, Brachman D, Podgorsak EB, Werner-Wasik M, Lustig R, Schultz CJ, Sause W, Okunieff P, Buckner J, Zamorano L, Mehta MP, Curran Jr WJ (2004) Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblasto-ma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 60: 853-860 (Pubitemid 39311766)
30. Soussain C, Ricard D, Fike JR, Mazeron J-J, Psimaras D, Delattre J-Y (2009) CNS complications of radiotherapy and chemotherapy. Lancet 374: 1639-1651
31. Spiegel BM, Esrailian E, Laine L, Chamberlain MC (2007) Clinical impact of adjuvant chemotherapy in glioblastoma multiforme : a meta-analysis. CNS Drugs 21: 775-787 (Pubitemid 47294722)
32. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet oncol 10: 459-466
33. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996 (Pubitemid 40349501)
34. Tapazoglou E, Lee M, Simpson J, Mohiuddin M, Nelson J, Kinzie J, Al-Sarraf M (1998) Concurrent azirdinyl-benzoquinone (AZQ) chemotherapy and radiotherapy (RT) in patients with malignant gliomas: RTOG Study. ASCO Annual Meeting, Los Angeles
35. Taphoorn MJB, Klein M (2004) Cognitive deficits in adult patients with brain tumours. Lancet Neurol 3: 159-168 (Pubitemid 38229950)
36. Tsien C, Moughan J, Michalski JM, Gilbert MR, Purdy J, Simpson J, Kresel JJ, Curran WJ, Diaz A, Mehta MP (2009) Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblas-toma: Radiation Therapy Oncology Group Trial 98-03. Int J Radiat Oncol Biol Phys 73: 699-708
37. Yung AW, Seiferheld W, Donahue B, Richards R, Kerlin K, Hug EB, Curran JW, Fine H (2001) A RTOG (Radiation Therapy Oncology Group) Phase II Study of Conventional Radiation Therapy Plus Thalidomide Followed by Thalidomide Post XRT for Supratentorial Glioblastoma. (Abstract 206) Proc Am Soc Clin Oncol 20